This summary was created by AI, based on 3 opinions in the last 12 months.
Viemed Healthcare (VMD-T) has shown positive momentum and growth, with recent earnings beating estimates and strong fundamentals. The company has seen revenue and earnings growth, with a positive cash flow and no debt. Despite a recent earnings miss, the overall results are considered decent, although the stock is highly volatile. The business continues to grow and trade at a reasonable PE, indicating a fundamentally sound business.
EPS of $0.04 missed estimates of $0.07 and revenues of $50.6M beat estimates of $49.9M. Revenues grew by 28% year-over-year, and its Adjusted EBITDA grew by 21%. It has no debt and management expects to generate revenues of $53.8M to $54.8M for Q2 2024. It was cash flow negative for the quarter, but its margins are good and it has a strong balance sheet. For a company growing fast with good profit margins, it is only trading at 20X forward earnings, but it is highly volatile and a small name. We consider the results overall decent, but investors are likely not pleased with its earnings miss.
Unlock Premium - Try 5i Free
Their numbers continues to soar, but shares fell last year over concerns that the hit diet drugs will impact them. But business continues to bs strong as they grow revenues and earnings. Trades at a reasonable PE.
(A Top Pick Jun 01/22, Up 73%)
Excellent performance in stock reflective of demand for healthcare tech.
Continues to hold.
Happy with results.
VMD EPS of 4c beat estimates of 3.5c; Revenue of $39.6M beat estimates of $38.5M. EBITDA of $8.3M beat estimates by 3%. Sales rose 23%; EPS though was flat year over year. EBITDA rose 15%. 2Q Guidance was maintained and another acquisition was announced. Cash rose to $23.5M (no debt). We would consider it a good quarter.
Unlock Premium - Try 5i Free
He didn't like it for a while, but now more than before. The telehealth space is getting crowded and they've had issues with CMS code. It's a good American company, though doesn't receive much attention here. VMS is merely okay. He prefers other names like Knight Therapeutics. It's a decent, second-tier company.
Viemed Healthcare is a Canadian stock, trading under the symbol VMD-T on the Toronto Stock Exchange (VMD-CT). It is usually referred to as TSX:VMD or VMD-T
In the last year, 3 stock analysts published opinions about VMD-T. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viemed Healthcare.
Viemed Healthcare was recommended as a Top Pick by on . Read the latest stock experts ratings for Viemed Healthcare.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Viemed Healthcare In the last year. It is a trending stock that is worth watching.
On 2023-12-21, Viemed Healthcare (VMD-T) stock closed at a price of $10.45.
Momentum has been improving recently and VMD is up 10% year-to-date. Recent earnings were positive with the stock beating EPS and revenue estimates and continuing to grow positively. The stock continues to look good fundamentally with positive, growing free cash flows and a net cah balance. Its valuation at 25x forward earnings is also not bad given the strong earnings and revenue growth expected over the next few years. We think it is be worth holding as it is a fundamentally sound business in our opinion.
Unlock Premium - Try 5i Free